Navigation Links
Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
Date:3/26/2008

tatements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with th
'/>"/>
SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Repligen Reports Positive Phase 2a Clinical Trial Results of RG2417 for Symptoms of Bipolar Disorder
2. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
3. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
4. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
5. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
6. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. Prolexys Pharmaceuticals Initiates Phase 1 Study
11. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results and ... 11:30 a.m. ET / 8:30 a.m. PTWhere: , ... Simply log onto our website listed above. If you ... replay of the webcast will be available for a ...
(Date:10/30/2014)... MAHWAH, N.J. , Oct. 30, 2014 ... PGA TOUR and Champions Tour, is rounding out its ... Cup Championship in Scottsdale, AZ. ... PGA TOUR and Champions Tour that the brand has ... destination designed to educate golf fans on the importance ...
(Date:10/30/2014)... , Oct. 30, 2014  Electronic health records ... a result of government initiatives and the considerable ... providers have invested over the past five years. ... health IT, and U.S. clinicians use them on ... http://photos.prnewswire.com/prnh/20141029/155278LOGO Frost & ...
Breaking Medicine Technology:Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 2Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 3Stryker Mobility Zone Makes Final Stop Of 2014 At Charles Schwab Cup Championship 4Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4
(Date:10/31/2014)... to life. The last stage, when two daughter cells ... dawn of cell biology in the Victorian era. For ... study this final step, when the dividing cell creates ... given to this process by those early biologists, cytokinesis, ... a highly active and organized series of events. Scientists ...
(Date:10/31/2014)... Friday. October 31, 2014 — A team from ... and the University of California, Santa Cruz, was ... Cancer Genomics Cloud Pilot contracts with the goal ... analysis of The Cancer Genome Atlas (TCGA) and ... required computing resources in one cloud environment. This ...
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... 31, 2014 Energy Textiles has recently ... new gear is now available online, and Energy Textile ... of Celliant infrared-active athletic gear over compression gear. , ... contract has been signed for Under Armour to provide ... next eight years. In light of this decision, Energy ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3
... BALTIMORE, May 6 Two scientists whose work has ... potentially treat muscular dystrophy have been chosen to receive ... P. Campbell, Ph.D. and Louis M. Kunkel, Ph.D., share ... work identifying the genes and proteins that cause muscular ...
... with DonationsFORT WORTH, Texas, May 6 As Mother,s ... the Cure(R) fundraising campaign, which rewards donors with five ... G. Komen for the Cure(R) with a minimum $25 ... by simply visiting www.aa.com/komen to ...
... But study suggests disturbances reversible with behavioral, environmental changes ... depression when their children are born are more likely ... run a higher risk of having early-onset depression during ... first six months of life, babies born to depressed ...
... are surrounded by a multitude of different accents ... English dialect pronounces words differently than we do, ... Psychologist Catherine Best from MARCS Laboratories, University of ... and Wesleyan University, report a ground-breaking study on ...
... Team ( www.mobilemassageteam.com ), a leading provider of ... and special affairs, today announced that the company will be ... Wellness Summit ( http://www.globalfit.com/summit/ ) held ... in Center City Philadelphia. Team members will be set ...
... Fight Against Tobacco Recognized Nationally--WASHINGTON, May 6 Kyle ... named the Central Regional Youth Advocate of the Year ... in the fight against tobacco. Kyle is being honored ... 6) along with a national winner, three other regional ...
Cached Medicine News:Health News:March of Dimes Awards $250,000 Prize to Scientists Unraveling the Causes of Muscular Dystrophy 2Health News:American Airlines Launches 2009 'Miles for the Cure' Campaign to Benefit Susan G. Komen for the Cure 2Health News:American Airlines Launches 2009 'Miles for the Cure' Campaign to Benefit Susan G. Komen for the Cure 3Health News:American Airlines Launches 2009 'Miles for the Cure' Campaign to Benefit Susan G. Komen for the Cure 4Health News:Maternal Depression Has Negative Effect on Infants' Sleep 2Health News:Campaign for Tobacco-Free Kids Honors Kyle Picha of Prairie du Chien, WI As Youth Advocate of the Year 2
A compact showcase unit. Made with tempered glass, one, two or three adjustable shelves, a door with a safety lock. Equipped with fluorescent lighting and levelers. Display is available in various si...
... Laboratories of America is the ... lens lab network in the ... in-house Crizal coating centers, Essilor ... ensure premium quality on the ...
Industry leader in the design and manufacturing of GP Lenses. Abba holds the CLMA seal of excellence award....
The inventory system designed for Wholesale Distributors and centralized distribution centers for Optical chains....
Medicine Products: